A new analysis from the DAPA-CKD trial found that the SGLT2 inhibitor dapagliflozin reduced the risk of kidney failure, death from cardiovascular causes or hospitalisation for heart failure, and prolonged survival in people with chronic kidney disease (CKD), with or without type 2 diabetes mellitus (T2DM). The benefits of dapagliflozin were independent of the presence of cardiovascular disease (CVD) [1,2].
Prof. John McMurray (University of Glasgow, Scotland) presented a new analysis of the randomised, double-blind, placebo-controlled DAPA-CKD trial (NCT03036150), which enrolled 4,304 patients to assess the impact of dapagliflozin 10 mg versus placebo alongside standard of care (i.e. ACE inhibitor or ARB) . Participants had a urinary albumin to creatinine ratio of ≥200 mg/g and an estimated glomerular filtration rate (eGFR) between 25–75 mL/min/1.73 m2
If you have no account yet, please
Please login to read the full text of the article.
« Deep and durable responses with ide-cel in RRMM Next Article
Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody »
Table of Contents: AHA 2020
COVID-19 and Influenza
CVD Risk Reduction
Acute Coronary Syndrome
Coronary and Valve Disease
If you have no account yet, please register now.